With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global Phase 2b trial in people with obesity or ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at ...

Entdecken Sie, wie Bayer als Arbeitgeber abschneidet und ob sich das Gehalt trotz der aktuellen Krise lohnt. Erfahren Sie ...

Im Glyphosat-Streit muss Bayer 2,1 Milliarden Dollar zahlen.

Mankind Pharma, India’s fourth largest drugmaker by domestic sales, is setting its sights on anti-obesity drugs like Semaglutide, better known by brand names Ozempic and Wegovy, which goes off ...

On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on ‘Squawk Box’ to discuss the potential challenges and opportunities the pharmaceutical industry may face under the ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

Stäubli Robotics in collaboration with a prominent pharmaceutical company has developed a mobile robot for use in Grade A/B/C/D cleanrooms. A cross-functional team ...

Es war das große Bayern-Experiment vor der Saison. Nachdem Wunsch-Trainer Xabi Alonso (43) nicht für den Trainer-­Posten beim FC Bayern zur Verfügung gestanden hatte – wie auch weitere ...

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...